Viracta Therapeutics, Inc. (VIRX)
USD 0.02
(14.44%)
USD 0.02
(14.44%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 50.69 Million USD | 0.22% |
| 2022 | 50.58 Million USD | 96.1% |
| 2021 | 25.79 Million USD | 37.11% |
| 2020 | 18.81 Million USD | -25.81% |
| 2019 | 25.36 Million USD | -2.22% |
| 2018 | 25.93 Million USD | -26.06% |
| 2017 | 35.07 Million USD | -10.02% |
| 2016 | 38.98 Million USD | -7.92% |
| 2015 | 42.33 Million USD | -16.62% |
| 2014 | 50.77 Million USD | 27.81% |
| 2013 | 39.72 Million USD | 3.57% |
| 2012 | 38.36 Million USD | 24.28% |
| 2011 | 30.86 Million USD | 43.97% |
| 2010 | 21.43 Million USD | 2.11% |
| 2009 | 20.99 Million USD | -44.47% |
| 2008 | 37.8 Million USD | -23.82% |
| 2007 | 49.63 Million USD | 3.68% |
| 2006 | 47.87 Million USD | 7.7% |
| 2005 | 44.44 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 13.76 Million USD | 2.45% |
| 2024 Q2 | 9.49 Million USD | -30.34% |
| 2023 Q3 | 12.47 Million USD | 0.2% |
| 2023 Q1 | 12.2 Million USD | 5.47% |
| 2023 Q2 | 12.45 Million USD | 1.99% |
| 2023 FY | 50.2 Million USD | -0.77% |
| 2023 Q4 | 13.43 Million USD | 7.71% |
| 2022 Q2 | 10.5 Million USD | 0.7% |
| 2022 FY | 50.58 Million USD | 96.1% |
| 2022 Q1 | 10.43 Million USD | -7.83% |
| 2022 Q4 | 11.57 Million USD | -35.98% |
| 2022 Q3 | 18.07 Million USD | 72.09% |
| 2021 Q2 | 9.31 Million USD | 265.31% |
| 2021 Q1 | -5.63 Million USD | -192.0% |
| 2021 Q4 | 11.31 Million USD | 4.81% |
| 2021 Q3 | 10.79 Million USD | 15.91% |
| 2021 FY | 25.79 Million USD | 37.11% |
| 2020 Q4 | 6.12 Million USD | 53.46% |
| 2020 Q1 | 4.45 Million USD | -39.99% |
| 2020 FY | 18.81 Million USD | -25.81% |
| 2020 Q2 | 4.24 Million USD | -4.87% |
| 2020 Q3 | 3.99 Million USD | -5.85% |
| 2019 Q2 | 6.2 Million USD | 9.13% |
| 2019 Q3 | 6.04 Million USD | -2.66% |
| 2019 Q4 | 7.42 Million USD | 22.94% |
| 2019 FY | 25.36 Million USD | -2.22% |
| 2019 Q1 | 5.68 Million USD | -1.27% |
| 2018 Q3 | 6.27 Million USD | -4.63% |
| 2018 FY | 25.93 Million USD | -26.06% |
| 2018 Q2 | 6.58 Million USD | -10.18% |
| 2018 Q1 | 7.32 Million USD | 13.89% |
| 2018 Q4 | 5.76 Million USD | -8.24% |
| 2017 Q4 | 6.43 Million USD | -35.26% |
| 2017 Q3 | 9.93 Million USD | 15.4% |
| 2017 FY | 35.07 Million USD | -10.02% |
| 2017 Q2 | 8.61 Million USD | -14.77% |
| 2017 Q1 | 10.1 Million USD | 15.49% |
| 2016 Q4 | 8.74 Million USD | -4.28% |
| 2016 Q3 | 9.14 Million USD | -13.8% |
| 2016 FY | 38.98 Million USD | -7.92% |
| 2016 Q2 | 10.6 Million USD | 0.94% |
| 2016 Q1 | 10.5 Million USD | -12.54% |
| 2015 FY | 42.33 Million USD | -16.62% |
| 2015 Q3 | 9.25 Million USD | -19.38% |
| 2015 Q4 | 12.01 Million USD | 29.8% |
| 2015 Q2 | 11.47 Million USD | 19.27% |
| 2015 Q1 | 9.62 Million USD | -20.14% |
| 2014 Q2 | 13.59 Million USD | 23.92% |
| 2014 FY | 50.77 Million USD | 27.81% |
| 2014 Q1 | 10.96 Million USD | 14.49% |
| 2014 Q4 | 12.05 Million USD | -14.93% |
| 2014 Q3 | 14.16 Million USD | 4.21% |
| 2013 Q4 | 9.58 Million USD | -1.87% |
| 2013 Q3 | 9.76 Million USD | -7.56% |
| 2013 FY | 39.72 Million USD | 3.57% |
| 2013 Q2 | 10.56 Million USD | 7.56% |
| 2013 Q1 | 9.82 Million USD | -2.4% |
| 2012 Q3 | 9.2 Million USD | -10.19% |
| 2012 FY | 38.36 Million USD | 24.28% |
| 2012 Q4 | 10.06 Million USD | 9.26% |
| 2012 Q1 | 8.83 Million USD | 4.12% |
| 2012 Q2 | 10.25 Million USD | 16.06% |
| 2011 Q3 | 8.37 Million USD | 5.64% |
| 2011 Q1 | 6.08 Million USD | -8.64% |
| 2011 Q2 | 7.92 Million USD | 30.26% |
| 2011 FY | 30.86 Million USD | 43.97% |
| 2011 Q4 | 8.48 Million USD | 1.35% |
| 2010 Q2 | 4.83 Million USD | 3.63% |
| 2010 FY | 21.43 Million USD | 2.11% |
| 2010 Q4 | 6.65 Million USD | 26.05% |
| 2010 Q3 | 5.28 Million USD | 9.31% |
| 2010 Q1 | 4.66 Million USD | 15.35% |
| 2009 FY | 20.99 Million USD | -44.47% |
| 2009 Q3 | 4.88 Million USD | -10.18% |
| 2009 Q2 | 5.44 Million USD | -17.76% |
| 2009 Q1 | 6.61 Million USD | -2.84% |
| 2009 Q4 | 4.04 Million USD | -17.31% |
| 2008 Q1 | 12 Million USD | 8.3% |
| 2008 Q3 | 7.49 Million USD | -34.85% |
| 2008 Q4 | 6.81 Million USD | -9.05% |
| 2008 Q2 | 11.49 Million USD | -4.26% |
| 2008 FY | 37.8 Million USD | -23.82% |
| 2007 Q3 | 12.19 Million USD | -11.25% |
| 2007 Q2 | 13.74 Million USD | 9.03% |
| 2007 Q1 | 12.6 Million USD | 6.44% |
| 2007 Q4 | 11.08 Million USD | -9.08% |
| 2007 FY | 49.63 Million USD | 3.68% |
| 2006 Q2 | 12 Million USD | -3.2% |
| 2006 Q4 | 11.84 Million USD | 1.81% |
| 2006 FY | 47.87 Million USD | 7.7% |
| 2006 Q1 | 12.39 Million USD | 22.4% |
| 2006 Q3 | 11.63 Million USD | -3.08% |
| 2005 Q3 | 8.93 Billion USD | 0.0% |
| 2005 FY | 44.44 Million USD | 0.0% |
| 2005 Q4 | 10.12 Million USD | -99.89% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -7566.447% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -446.968% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -69.016% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 24.504% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -219.971% |
| Better Therapeutics, Inc. | 38.26 Million USD | -32.489% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -24.586% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -309.054% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -49.784% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -47.282% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 53.264% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -5006.017% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -55.552% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -7.97% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -4073.335% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -154.237% |
| Molecular Templates, Inc. | 63.09 Million USD | 19.651% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -263.871% |
| NexImmune, Inc. | 28.16 Million USD | -79.97% |
| Orgenesis Inc. | 45.75 Million USD | -10.787% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -97.657% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -68948.981% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -213.98% |
| Scopus BioPharma Inc. | 11.71 Million USD | -332.723% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 87.439% |
| Statera Biopharma, Inc. | 28.82 Million USD | -75.837% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -167.806% |
| Trevena, Inc. | 38.41 Million USD | -31.968% |
| Vaxxinity, Inc. | 56.05 Million USD | 9.559% |
| Vaccinex, Inc. | 23.45 Million USD | -116.129% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -4741.84% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -596.847% |